Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$81,365.00-0.12%ETH$2,399.97+0.22%GOLD$4,010.00-1.24%OIL$103.44+3.99%
Smart Investors Daily
SID Premium
AD

OTC · ADAPY

Adaptimmune Therapeutics plc

Healthcare · Biotechnology

$0.03

Up+$0.01 (+20.00%)

Updated Oct 23, 2026, 9:26 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.3M
P/E ratio
-0.03
Dividend yield
0.00%
52-week range
— – —
Volume
37.58K
Avg. volume
2.26M

Price performance · ADAPY

ADAPY price history

1M range · 0 trading sessions · Daily adjusted prices

ADAPY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ADAPY news

The latest Smart Investors Daily articles mentioning ADAPY.

Stock researchCompany · Overview

ADAPY research

Overview

Company profile and research snapshot.

Company profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.83
Implied upside
—
Analysts
—
ADAPY recent ratings
DateFirmRatingTarget
Jul 29, 2025HC Wainwright & Co.Neutral—
Jun 26, 2025MizuhoNeutral—
May 14, 2025BarclaysUnderweight—
May 14, 2025Wells FargoEqual-Weight—
Apr 1, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

newsfilecorp.com · Nov 17, 2025

Adaptimmune Announces Changes to Board and Executive Leadership Team

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes to the Company's Board of Directors ("Board") and its Executive Leadership team, which are effective from November 14, 2025. Christopher (Chris) Hill, currently Chief Financial Officer ("CFO") of the Company, has been appointed as Chief Executive Officer ("CEO") and a Director of the Company, succeeding Adrian Rawcliffe who has left in connection with the Company's restructuring.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By